Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
about
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyDurable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case reportEarly and late onset complications of gynaecologic surgery: a multimodality imaging approachHigh expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma.Diagnosis and treatment of sarcoma of the uterus. A review.Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrenceAn immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.Immunohistochemical profile of uterine leiomyomas; a comparison between different subtypesImmunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.Hormonal therapy in gynecological sarcomas.Prognostic role of Twist or Snail in various carcinomas: a systematic review and meta-analysis.Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.The expression and characterization of endoglin in uterine leiomyosarcoma.The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumours: an outcome-based study.Uterine sarcomas.A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival.Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model.YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations.Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors.Immunoexpression of p16 in uterine leiomyomas with infarct-type necrosis: an analysis of 35 cases.Oncomirs Expression Profiling in Uterine Leiomyosarcoma Cells.TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
P2860
Q30370631-D0373EE9-0912-4D3F-B755-B25A24A8485CQ33582227-ADFC8F65-0AD7-4D65-88D0-32A8DCE0BE8EQ33896879-7969DEA4-340F-44E8-9F5F-3C7828307279Q33898629-1062FD68-DFD0-4C8D-B811-FC843167BF55Q34336818-EFD8BAD4-58EA-4D12-9197-0B5A7D8238ACQ35152557-C4F8D19D-544C-4BD2-BDD5-D9D6D5E158D9Q35601947-938AD3EE-FBAE-4A4D-B219-63929E439366Q35632172-64D6DDF7-83AC-4EF0-B175-DBA95139E61BQ36690945-E3E0A681-59B2-49FA-9D77-34B922F03534Q36876722-7AC51B66-CC73-4EB4-9EC1-ECC3E3E51C33Q37821354-3733D1CD-D462-475A-AA0A-24E1BAE31708Q38030590-08681231-3BD1-49FC-8E3E-AF5095063A5DQ38254499-7174B1AA-58E1-4027-8C6C-1F6FDCC599D8Q38927258-6AC280EA-AABC-40C4-9073-C0B5138E00D6Q39196836-4060611E-2375-42B9-A000-6D25A88F950BQ40466987-39B56302-E780-4669-AD6A-9AF04E1B9C1AQ41266926-DA454EE3-BDF6-4EA5-BEC8-0856DC12BE1DQ44433131-7385159E-6DC5-41C5-8089-51980AEFDD53Q45199929-FA5823AB-7E14-4A9C-AAA5-32AC0EC62500Q45333978-9965356B-A671-4FFE-B68C-645879571E2AQ47228185-28441FB7-5099-4447-A564-453AA3C9C54BQ48284107-319A5E78-87EA-4F3A-AF15-05F49CFEF5FDQ48319823-6741EE1F-ECD6-40C2-AB81-8254E117F073Q48845796-FA545A28-CF9D-46ED-A4F8-020D68C5CF45Q54647189-06EDBFE6-AB31-4CB6-BBEC-BA5F41097C27
P2860
Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Comparative clinicopathologic ...... ization classification system.
@en
Comparative clinicopathologic ...... ization classification system.
@nl
type
label
Comparative clinicopathologic ...... ization classification system.
@en
Comparative clinicopathologic ...... ization classification system.
@nl
prefLabel
Comparative clinicopathologic ...... ization classification system.
@en
Comparative clinicopathologic ...... ization classification system.
@nl
P1433
P1476
Comparative clinicopathologic ...... ization classification system.
@en
P2093
Emanuela D'Angelo
Jaime Prat
P304
P356
10.1016/J.HUMPATH.2009.03.018
P407
P577
2009-06-21T00:00:00Z